{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:43:21Z","timestamp":1762145001449,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177918","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:26:05Z","timestamp":1751635565000},"page":"177918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MiR-216a-5p inhibits proliferation, migration, and enhances oxaliplatin sensitivity by targeting ZBTB2 in gastric cancer cells"],"prefix":"10.1016","volume":"1003","author":[{"given":"Xiao-Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Long","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Huang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Shun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177918_bib1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177918_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009364","article-title":"ZBTB2 represses HIV-1 transcription and is regulated by HIV-1 vpr and cellular DNA damage responses","volume":"17","author":"Bruce","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2025.177918_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.778096","article-title":"Upregulation of miR-216a-5p by lentinan targeted inhibition of JAK2\/STAT3 signaling pathway to reduce lung adenocarcinoma cell stemness, promote apoptosis, and slow down the lung adenocarcinoma mechanisms","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168162","article-title":"ZBTB2 is recruited to a specific subset of HIF-1 target loci to facilitate full gene expression under hypoxia","volume":"435","author":"Chow","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.177918_bib5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s13402-023-00835-4","article-title":"LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing","volume":"46","author":"Deng","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681736","article-title":"AUF1 promotes proliferation and invasion of thyroid cancer via downregulation of ZBTB2 and subsequent TRIM58","volume":"11","author":"Du","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2025.177918_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684807","article-title":"The regulatory network and potential role of LINC00973-miRNA-mRNA ceRNA in the progression of non-small-cell lung cancer","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.177918_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12935-023-02865-2","article-title":"Molecular mechanisms of microRNA-216a during tumor progression","volume":"23","author":"Hamidi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.177918_bib10","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.3390\/ijms23137167","article-title":"MicroRNA-based diagnosis and therapy","volume":"23","author":"Ho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177918_bib11","doi-asserted-by":"crossref","first-page":"17935","DOI":"10.1074\/jbc.M809559200","article-title":"ZBTB2, a novel master regulator of the p53 pathway","volume":"284","author":"Jeon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177918_bib12","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154042","article-title":"ZBTB2 links p53 deficiency to HIF-1-mediated hypoxia signaling to promote cancer aggressiveness","volume":"24","author":"Koyasu","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejphar.2025.177918_bib13","article-title":"circDNMT1 promotes malignant progression of gastric cancer through targeting miR-576-3p\/hypoxia inducible factor-1 alpha axis","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib14","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.7150\/jca.64730","article-title":"LncRNA HCP5 enhances the proliferation and migration of cervical cancer via miR-216a-5p\/CDC42 axis","volume":"13","author":"Li","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2025.177918_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fonc.2020.01062","article-title":"TIPRL, a novel tumor suppressor, suppresses cell migration, and invasion through regulating AMPK\/mTOR signaling pathway in gastric cancer","volume":"10","author":"Luan","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.845261","article-title":"Adjuvant chemotherapy in pT2N0M0 gastric cancer: findings from a retrospective study","volume":"13","author":"Mei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177918_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1397344","article-title":"Overview of microRNA biology","volume":"35","author":"Mohr","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejphar.2025.177918_bib18","doi-asserted-by":"crossref","first-page":"17330","DOI":"10.1074\/jbc.C700079200","article-title":"A proteomic analysis of ataxia telangiectasia-mutated (ATM)\/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints","volume":"282","author":"Mu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177918_bib19","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib20","article-title":"Sparse spectral graph analysis and its application to gastric cancer drug resistance-specific molecular interplays identification","volume":"19","author":"Park","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177918_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib22","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/hed.27779","article-title":"The novel circ_0004674\/miR-139-5p\/ZBTB2 regulatory cascade inhibits the development of oral squamous cell carcinoma","volume":"46","author":"Qi","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.ejphar.2025.177918_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100936","article-title":"Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer","volume":"68","author":"Qu","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejphar.2025.177918_bib24","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.7150\/jca.27546","article-title":"LncRNA GACAT1 promotes gastric cancer cell growth, invasion and migration by regulating miR-149-mediated of ZBTB2 and SP1","volume":"9","author":"Shi","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2025.177918_bib25","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.4161\/cc.21277","article-title":"The BTB-ZF transcription factors","volume":"11","author":"Siggs","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejphar.2025.177918_bib26","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2025.177918_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231206003","article-title":"The role of microRNAs in regulating cancer cell response to oxaliplatin-containing regimens","volume":"22","author":"Tavakoli Pirzaman","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.177918_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbrc.2018.08.150","article-title":"LncRNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316","volume":"504","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.177918_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib30","article-title":"MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177918_bib31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41419-022-05271-0","article-title":"Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5","volume":"13","author":"Woo","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.177918_bib32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fcell.2020.00812","article-title":"MicroRNA: another pharmacological avenue for colorectal cancer?","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.177918_bib33","doi-asserted-by":"crossref","first-page":"18702","DOI":"10.1002\/jcb.29178","article-title":"MicroRNA-488-3p inhibits proliferation and induces apoptosis by targeting ZBTB2 in esophageal squamous cell carcinoma","volume":"120","author":"Yang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.177918_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/15384101.2022.2146839","article-title":"Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253","volume":"22","author":"Yu","year":"2023","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejphar.2025.177918_bib35","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.7150\/ijbs.46822","article-title":"MiR-216a-5p inhibits tumorigenesis in pancreatic cancer by targeting TPT1\/mTORC1 and is mediated by LINC01133","volume":"16","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2025.177918_bib36","article-title":"Downregulation of long noncoding RNA HCP5\/miR-216a-5p\/ZEB1 axis inhibits the malignant biological function of laryngeal squamous cell carcinoma cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.177918_bib37","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1002\/jcp.29458","article-title":"MiR-4282 inhibits tumor progression through down-regulation of ZBTB2 by targeting LIN28B in oral squamous cell carcinoma","volume":"235","author":"Zhang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2025.177918_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fcell.2020.00348","article-title":"HOTTIP predicts poor survival in gastric cancer patients and contributes to cisplatin resistance by sponging miR-216a-5p","volume":"8","author":"Zhao","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.177918_bib39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12935-021-02416-7","article-title":"Glucose starvation suppresses gastric cancer through targeting miR-216a-5p\/Farnesyl-Diphosphate farnesyltransferase 1 axis","volume":"21","author":"Zhao","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.177918_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987650","article-title":"miRNA-21 May serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients","volume":"13","author":"Zhao","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejphar.2025.177918_bib41","first-page":"2428","article-title":"OIP5-AS1 promotes the progression of gastric cancer cells via the miR-153-3p\/ZBTB2 axis","volume":"24","author":"Zhi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:31:37Z","timestamp":1762144297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925006727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":41,"alternative-id":["S0014299925006727"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177918","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-216a-5p inhibits proliferation, migration, and enhances oxaliplatin sensitivity by targeting ZBTB2 in gastric cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177918"}}